What is the difference between Skyrizi (IL-23 inhibitor) and Rinvoq (JAK inhibitor)?

Skyrizi (risankizumab) targets IL-23, a cytokine (signaling protein) that drives Th17 immune cell activity — a pathway central to psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. By selectively blocking IL-23, Skyrizi reduces inflammation in these specific conditions with a targeted mechanism. Rinvoq (upadacitinib) is a JAK (Janus Kinase) inhibitor — it blocks JAK1, an enzyme inside immune cells that transmits inflammatory signals from multiple cytokines (including IL-6, IFN-gamma, and others). JAK inhibitors are broader in mechanism, affecting multiple inflammatory pathways. Rinvoq is approved for rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, Crohn's, UC, and ankylosing spondylitis. JAK inhibitors carry FDA black box warnings about increased risk of serious cardiovascular events, malignancies, and thrombosis versus biologics — this limits some patient populations but doesn't prevent broad use in appropriate patients.

What is Keytruda's competitive position across cancer indications?

Keytruda (pembrolizumab) is a PD-1 checkpoint inhibitor like BMS's Opdivo — it blocks the PD-1/PD-L1 interaction that tumor cells use to suppress T-cell attack. Keytruda has FDA approval in over 40 cancer type/treatment line combinations, making it the most broadly approved cancer therapy in history. Keytruda's competitive dominance in oncology resulted from: aggressive clinical development across many cancer types simultaneously; first-mover approvals in key indications including non-small cell lung cancer as first-line therapy, which drove massive adoption and created prescribing habit among oncologists; biomarker strategy (using PD-L1 expression and tumor mutational burden to select patients most likely to respond); and commercial execution. Opdivo has meaningful positions in specific settings (renal cell carcinoma, hepatocellular carcinoma) but Keytruda has displaced Opdivo as the dominant checkpoint inhibitor in most cancer types. Keytruda generated approximately $25 billion in 2023 revenue.

What is a biosimilar and why is it different from a generic drug?

A generic drug is an exact copy of a small-molecule drug whose patent has expired — same active ingredient, same molecular structure. Generic manufacturing is straightforward because the molecule is simple and can be chemically synthesized identically. A biosimilar is an approximation of a biologic drug (a large, complex protein molecule produced by living cells) — biologics like Humira and Keytruda are antibodies with thousands of amino acids produced in complex cell culture systems. Two manufacturers running similar but not identical cell culture processes will produce antibodies that are 'highly similar' but not exactly identical (minor differences in glycosylation patterns and other post-translational modifications). Regulatory agencies (FDA, EMA) approve biosimilars after proving they have no clinically meaningful differences in safety and efficacy from the reference biologic. Biosimilars typically enter the market at 10-30% discounts to the originator biologic (not 80-90% discounts like generics) because they cost much more to manufacture than small-molecule generics.

Data as of: September 18, 2026

brimindinvest.com / compare / abbv-vs-mrkLIVE

ABBV

AbbVie Inc. · Healthcare - Pharmaceuticals

$264.02

+1.97% this month

VERSUS

COMPARE

MRK

Merck & Co., Inc. · Healthcare - Pharmaceuticals

$147.15

+8.86% this month

Comparison scoreboard

ABBV LEADS 3/5

AI Scorei

ABBV ✓53.2

MRK 51.4

1Y Returni

ABBV +22.08%

MRK ✓+81.47%

Fwd P/Ei

ABBV 15.79

MRK ✓15.55

Target Up.i

ABBV ✓+7.85%

MRK +0.26%

Op. Margini

ABBV ✓40.03%

MRK -0.24%

Metrics last refreshed: 9/18/2026

Quick take

ABBV vs MRK Stock Comparison: AI Score, Valuation, Performance and Upside

ShareX LinkedIn Reddit Facebook WhatsApp

ABBV (AbbVie) and MRK (Merck) are both large pharmaceutical companies with blockbuster franchises facing patent cliffs — AbbVie is successfully executing a post-Humira transition with Skyrizi and Rinvoq growing rapidly to replace Humira revenue, while Merck's Keytruda dominates oncology but faces its own patent cliff around 2028 with the pipeline challenge of building successors to the world's most successful cancer drug.

ABBV vs MRK is immunology franchise successfully navigating post-Humira transition (AbbVie's Skyrizi and Rinvoq immunology successors growing faster than Humira declined, demonstrating AbbVie's ability to regenerate franchise value after a massive patent expiry) versus oncology checkpoint inhibitor giant facing its own 2028 pipeline challenge (Merck's Keytruda dominance across 40+ cancer indications generating maximum revenue while Merck builds the post-Keytruda pipeline) — completed patent transition versus impending patent cliff.

Live analysis · updated 9/18/2026

ABBV holds the edge across 3 of 5 key metrics in this comparison. MRK leads on both 1-year return (+81.47%) and forward P/E quality (15.55x vs 15.79x for ABBV), a relatively favorable combination of momentum and valuation. ABBV leads on both revenue growth (10.20%) and operating margin (40.03%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for ABBV (+7.85%) than for MRK (+0.26%).

Normalized 1Y performance

ABBV

MRK

Recent returns

ABBV

MRK

Analyst price targets & sentiment

Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.

ABBV · 27 analysts

STRONG BUYHOLDSTRONG SELL

Buy (2.0/5.0)

24 Buy / 5 Hold / 1 Sell

Price target range

analyst low$170.00
analyst mean$277.31
current price$264.02

+7.9% upside to analyst mean

MRK · 24 analysts

STRONG BUYHOLDSTRONG SELL

Buy (2.0/5.0)

20 Buy / 8 Hold / 0 Sell

Price target range

analyst low$82.00
analyst mean$148.73
current price$147.15

+0.3% upside to analyst mean

Who should consider this stock?

ABBV may suit investors who:

Want a successful post-LOE pharmaceutical transition story — AbbVie has demonstrated it can grow revenue even after losing Humira exclusivity, with Skyrizi and Rinvoq exceeding expectations
Value AbbVie's high and growing dividend (AbbVie is a Dividend Aristocrat) as attractive income from a pharmaceutical company with durable immunology franchise revenue
Value the Allergan aesthetics business as providing a non-pharmaceutical revenue stream tied to consumer aesthetics spending that diversifies AbbVie beyond prescription drugs

MRK may suit investors who:

Want the global oncology immunotherapy leader — Merck's Keytruda is the most prescribed cancer treatment globally and continues gaining new indications and earlier lines of therapy, providing multi-year revenue growth runway before its 2028 LOE
Value Merck's Gardasil global HPV vaccination franchise as a durable preventive healthcare revenue stream alongside the oncology business
Are willing to accept the 2028 Keytruda patent cliff as a future risk while capturing Keytruda's current growth and believe Merck can build a sufficient post-Keytruda pipeline

Performance & AI score

Performance & AI score
Metric	ABBV	MRK
AI scorei	53.2	51.4
AI ranki	#353	#455
Latest closei	$264.02	$147.15
1M returni	+1.97%	+8.86%
6M returni	+28.02%	+28.85%
1Y returni	+22.08%	+81.47%

$10,000 invested — hypothetical growth (dividends reinvested)

How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?

$10,000 invested — hypothetical growth (dividends reinvested)
Period	ABBV	MRK
1Y ago	$11.96K (+19.6%) started 2025-09-17	$18.14K (+81.4%) started 2025-09-17
5Y ago	$33.48K (+234.8%) started 2021-09-20	$25.31K (+153.1%) started 2021-09-20
10Y ago	$95.11K (+851.1%) started 2016-09-19	$43.47K (+334.7%) started 2016-09-19

Hypothetical — past performance does not guarantee future results.

Valuation & upside potential

Valuation & upside potential
Metric	ABBV	MRK
Market capi	$454.36B	$366B
Trailing P/Ei	72.43	118.68
Forward P/Ei	15.79	15.55
Price/Salesi	5.85	3.10
EV/Revenuei	8.06	6.20
Analyst targeti	$277.31	$148.73
Target upsidei	+7.85%	+0.26%

Growth, profitability & risk

Growth, profitability & risk
Metric	ABBV	MRK
Revenue growthi	10.20%	5.10%
Earnings growthi	290.40%	-19.30%
EPS growthi	+290.40%	-19.30%
FCF margini	+26.20%	+22.79%
Operating margini	40.03%	-0.24%
Profit margini	9.80%	4.77%
ROIC proxyi	6225.00%	6.96%
Return on equityi	6225.00%	6.96%
Dividend yieldi	2.69%	2.29%
Payout ratioi	190.40%	268.80%
Dividend growth streaki	No increase yet	No increase yet
Betai	0.28	0.21
Debt/equityi	4789.60	128.41
Current ratioi	0.81	1.32
Quick ratioi	0.49	0.74

Correlation

Over the past year, ABBV and MRK have moved moderately in the same direction (correlation of 0.46), based on daily returns.

1Y

0.46

-1.0+1.0

5Y

0.41

-1.0+1.0

10Y

0.44

-1.0+1.0

Drawdown & downside risk

Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.

1Y risk snapshot

ABBV max drawdowni19.23%

MRK max drawdowni11.90%

ABBV max wkly dropi8.49%

MRK max wkly dropi6.49%

5Y risk snapshot

ABBV max drawdowni21.92%

MRK max drawdowni43.44%

ABBV max wkly dropi17.30%

MRK max wkly dropi13.42%

10Y risk snapshot

ABBV max drawdowni45.09%

MRK max drawdowni43.44%

ABBV max wkly dropi19.39%

MRK max wkly dropi13.71%

Performance metrics by period

Performance metrics by period
Period	Metric	ABBV	MRK
1Y	Growthi	+19.57%	+81.35%
	CAGRi	+19.60%	+81.51%
	Volatilityi	26.44%	30.47%
	Sharpe ratioi	0.64	1.97
	Sortino ratioi	0.98	3.71
	Max drawdowni	19.23%	11.90%
	Current drawdowni	0.73%	5.94%
	Avg drawdowni	7.66%	3.58%
	Ulcer Indexi	9.00%	4.66%
	Max daily dropi	5.20%	4.06%
	Max wkly dropi	8.49%	6.49%
5Y	Growthi	+186.68%	+127.04%
	CAGRi	+23.49%	+17.85%
	Volatilityi	23.38%	24.95%
	Sharpe ratioi	0.83	0.61
	Sortino ratioi	1.16	0.89
	Max drawdowni	21.92%	43.44%
	Current drawdowni	0.73%	5.94%
	Avg drawdowni	8.02%	12.57%
	Ulcer Indexi	9.98%	17.29%
	Max daily dropi	12.57%	9.86%
	Max wkly dropi	17.30%	13.42%
10Y	Growthi	+508.37%	+225.00%
	CAGRi	+19.80%	+12.52%
	Volatilityi	26.02%	23.35%
	Sharpe ratioi	0.65	0.43
	Sortino ratioi	0.91	0.62
	Max drawdowni	45.09%	43.44%
	Current drawdowni	0.73%	5.94%
	Avg drawdowni	11.54%	9.82%
	Ulcer Indexi	15.57%	13.74%
	Max daily dropi	16.25%	9.86%
	Max wkly dropi	19.39%	13.71%

AI Prediction Signali

Members only

Next 5 trading days

ABBV

+2.8%BUY

MRK

+1.1%HOLD

Next 30 trading days

ABBV

+6.4%BUY

MRK

+3.2%HOLD

Start Free Trial Log in

ML model trained on historical prices · 14-day free trial · No credit card required

Business comparison

Business comparison
Category	ABBV	MRK
Company	AbbVie Inc.	Merck & Co., Inc.
Sector	Healthcare	Healthcare
Industry	Drug Manufacturers - General	Drug Manufacturers - General
Core business	AbbVie is a global biopharmaceutical company specializing in immunology and oncology — with its commercial franchise anchored by Humira (adalimumab, anti-TNF biologic for rheumatoid arthritis, psoriasis, IBD) and successors Skyrizi (risankizumab, IL-23 inhibitor for psoriasis, Crohn's, UC) and Rinvoq (upadacitinib, JAK inhibitor for RA, psoriasis, Crohn's). AbbVie acquired Allergan in 2020, adding Botox aesthetics, Juvederm, and Vraylar to its portfolio.	Merck is a global pharmaceutical leader with its commercial franchise dominated by Keytruda (pembrolizumab, PD-1 checkpoint inhibitor for 40+ cancer indications), Gardasil/Gardasil 9 (HPV vaccines, the global standard for cervical cancer prevention), Januvia/Janumet (sitagliptin, type 2 diabetes), and a growing oncology and vaccines pipeline. Merck's animal health division is a major veterinary medicine business.
Investor focus	Investors track AbbVie's revenue recovery as Humira loses exclusivity (biosimilar competition reducing Humira's U.S. revenue), the Skyrizi and Rinvoq growth trajectory replacing and exceeding Humira's peak revenue, Allergan aesthetics segment performance, and the oncology and neuroscience pipeline.	Investors track Keytruda's quarterly revenue growth across cancer indications, the pending Keytruda LOE (U.S. patent expiry around 2028) and pipeline candidates to succeed Keytruda, Gardasil volumes particularly in China (a large growth market), and oncology pipeline readouts that could address the post-Keytruda revenue challenge.

ABBV strengths

Skyrizi and Rinvoq are growing faster than Humira declined — AbbVie's newer immunology drugs are capturing market share in rheumatology, dermatology, and gastroenterology; combined, Skyrizi and Rinvoq are on track to generate more revenue than Humira at its peak
Allergan aesthetics provides diversification with injectables growth — Botox Cosmetic and Juvederm (dermal fillers) serve the premium medical aesthetics market; aesthetic procedures are semi-elective but grow with aging demographic trends and increasing consumer acceptance of cosmetic treatments
Broad immunology franchise across RA, IBD, and dermatology — AbbVie's drugs serve patients with chronic immune conditions who typically remain on biologic therapy for years or decades, creating durable recurring revenue

MRK strengths

Keytruda dominates oncology immunotherapy — pembrolizumab is approved for 40+ cancer type/line combinations and is the most prescribed immunotherapy globally; Keytruda's breadth across lung, melanoma, head and neck, bladder, kidney, MSI-H solid tumors, and many others creates unmatched oncology scope
Gardasil global HPV vaccination leadership — Gardasil 9 is the standard HPV vaccine preventing cervical, oropharyngeal, anal, and other HPV-related cancers; global vaccination programs provide long-term vaccine revenue with emerging market expansion potential
Oncology pipeline building toward post-Keytruda future — Merck has multiple next-generation oncology assets (Winrevair for pulmonary hypertension, antibody-drug conjugates, bispecific antibodies) and subcutaneous Keytruda formulations extending the franchise

Risks to watch — ABBV

Humira biosimilar competition reducing revenue significantly — the introduction of Humira biosimilars (Hadlima, Hyrimoz, Cyltezo and others) in 2023 has dramatically reduced Humira's U.S. revenue as payers shift to lower-cost biosimilars; while expected, the transition is a multi-billion dollar revenue headwind
Skyrizi and Rinvoq safety profile monitoring — JAK inhibitors (Rinvoq) carry FDA safety warnings about cardiovascular events, malignancies, and thrombosis; label restrictions and post-marketing safety data could affect Rinvoq's market penetration
Allergan aesthetics cyclicality — cosmetic Botox and filler purchases are discretionary; consumer spending slowdowns affect aesthetic injection volumes more than prescription pharmaceuticals

Risks to watch — MRK

Keytruda LOE around 2028 is a significant financial event — Keytruda generates ~$25 billion annually; biosimilar competition after 2028 LOE could dramatically reduce this revenue; Merck must develop pipeline assets to offset this cliff
Gardasil China volume dependence — China became a major Gardasil growth market; if Chinese health authorities reduce national vaccination programs or preferential access changes, Gardasil China volumes could decline materially
Competition from Bristol-Myers Squibb's Opdivo and emerging checkpoint inhibitor combinations — while Keytruda leads in most settings, competitive data from combination regimens could chip away at specific Keytruda indications

Frequently asked questions

Humira (adalimumab) is a monoclonal antibody that targets TNF-alpha (Tumor Necrosis Factor-alpha), an inflammatory protein overproduced in conditions like rheumatoid arthritis, psoriasis, Crohn's disease, and ulcerative colitis. By blocking TNF-alpha, Humira reduces inflammation that causes joint damage, skin plaques, and bowel inflammation. Humira achieved peak annual global sales of approximately $21 billion, making it the best-selling drug in history for many consecutive years. Its commercial success resulted from: broad indications approved across 10+ inflammatory conditions; long duration of therapy (patients take Humira for years or decades without stopping if it works); premium pricing ($15,000-25,000 annually in the U.S.); limited competition from biosimilars until 2023 in the U.S. (despite EU biosimilar entry in 2018, AbbVie negotiated delayed U.S. entry for the biosimilar makers).

Free public comparison

Want deeper AI forecasts?

This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.

Start Free Trial Read Investing Guides

Related comparisons